Citius Pharma(CTXR) - 2026 Q1 - Quarterly Results

Financial Performance - Citius Pharmaceuticals reported $3.9 million in revenue for the fiscal first quarter 2026, generated from initial sales of LYMPHIR in December 2025[1][2]. - The net loss applicable to common stockholders was $8.2 million, or $(0.38) per share, compared to a net loss of $9.8 million, or $(1.30) per share, in the prior-year period[8][15]. - Net loss for 2025 was $9,393,889, an improvement from a net loss of $10,281,246 in 2024[17]. - Stock-based compensation expense increased to $4,280,227 in 2025 from $2,524,824 in 2024[17]. - Net cash used in operating activities rose to $13,008,822 in 2025 compared to $4,725,852 in 2024[17]. Cash and Financing - Cash and cash equivalents totaled $7.7 million as of December 31, 2025, with net proceeds of approximately $20.9 million from equity financings during the quarter[8]. - Net proceeds from common stock offerings significantly increased to $20,877,925 in 2025 from $2,574,051 in 2024[17]. - Cash and cash equivalents at the end of the period reached $7,721,393 in 2025, up from $1,100,079 in 2024[17]. Research and Development - Research and development expenses decreased to $1.6 million from $2.1 million in the prior-year period, reflecting reduced clinical development activity[8]. - Citius Pharma is advancing its late-stage pipeline, which includes Mino-Lok and Halo-Lido, with ongoing engagement with the FDA[4][8]. Market Strategy and Opportunities - The company aims to expand patient access and market penetration through a technology-driven platform and anticipates growth from international market opportunities[3]. - Citius Oncology's LYMPHIR is targeted for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma, with an estimated initial market exceeding $400 million[5][9]. - The company has initiated agreements for international patient access to LYMPHIR through Named Patient Programs in Europe and the Middle East[8]. - Citius Oncology has deployed an AI-enabled commercial platform to enhance physician engagement and market penetration in a concentrated prescriber base[8]. Operational Changes - General and administrative expenses increased to $5.7 million compared to $5.4 million in the prior-year period[8]. - License fee payments in investing activities amounted to $4,400,000 in 2025, with no such payments in 2024[17]. - Changes in accounts receivable resulted in a decrease of $4,049,111 in 2025, with no allowances reported in 2024[17]. - Inventory decreased by $352,649 in 2025, a significant improvement compared to a decrease of $6,112,603 in 2024[17]. - Accrued expenses decreased by $5,722,097 in 2025, contrasting with an increase of $6,225,151 in 2024[17]. - Interest paid in 2025 was $14,460, with no interest paid reported in 2024[17].